Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

doi:10.1016/j.jaad.2011.11.804

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.804 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB191

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Interleukin 17A

Download Full-text

Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

British Journal of Dermatology ◽

10.1111/bjd.17628 ◽

2019 ◽

Vol 181 (1) ◽

pp. 88-95 ◽

Cited By ~ 21

Author(s):

K. Reich ◽

P. Rich ◽

C. Maari ◽

R. Bissonnette ◽

C. Leonardi ◽

...

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Randomized Phase Ii

Download Full-text

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2012.04716.x ◽

2012 ◽

Vol 27 (3) ◽

pp. e376-e383 ◽

Cited By ~ 67

Author(s):

K.A. Papp ◽

R. Kaufmann ◽

D. Thaçi ◽

C. Hu ◽

D. Sutherland ◽

...

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Comparison Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Dose Comparison ◽

Parallel Group

Download Full-text

Secukinumab efficacy and safety outcomes from a phase II subcutaneous dose-ranging study in the treatment of moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.849 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB203

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Subcutaneous Dose ◽

Safety Outcomes ◽

Dose Ranging

Download Full-text

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

Journal of Dermatological Science ◽

10.1016/j.jdermsci.2015.10.009 ◽

2016 ◽

Vol 81 (1) ◽

pp. 44-52 ◽

Cited By ~ 56

Author(s):

Hidemi Nakagawa ◽

Hiroaki Niiro ◽

Kenji Ootaki

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Receptor Antibody ◽

Randomized Controlled

Download Full-text

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

Vestnik dermatologii i venerologii ◽

10.25208/0042-4609-2017-93-5-52-63 ◽

2017 ◽

pp. 52-63 ◽

Cited By ~ 8

Author(s):

A. V. Samtsov ◽

V. R. Khairutdinov ◽

A. L. Bakulev ◽

A. A. Kubanov ◽

A. E. Karamova ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Plaque Psoriasis ◽

Phase Ii Clinical Trial ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

British Journal of Dermatology ◽

10.1111/bjd.12110 ◽

2013 ◽

Vol 168 (2) ◽

pp. 412-421 ◽

Cited By ~ 230

Author(s):

K.A. Papp ◽

R.G. Langley ◽

B. Sigurgeirsson ◽

M. Abe ◽

D.R. Baker ◽

...

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962524.793471094 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Dose Ranging

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15789 ◽

2021 ◽

Author(s):

Atsuyuki Igarashi ◽

Hidemi Nakagawa ◽

Akimichi Morita ◽

Yukari Okubo ◽

Shigetoshi Sano ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis

Download Full-text

15190 Whole blood transcriptomic profiling in a phase 3 study of the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.213 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB31

Author(s):

Shaojun Tang ◽

Arnaud Amzallag ◽

Robert Yang ◽

Peter H. Schafer

Keyword(s):

Plaque Psoriasis ◽

Whole Blood ◽

Efficacy And Safety ◽

Phase 3 ◽

Transcriptomic Profiling ◽

Severe Plaque Psoriasis

Download Full-text